<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05629767</url>
  </required_header>
  <id_info>
    <org_study_id>JCCG.JoLLA.10.2022</org_study_id>
    <nct_id>NCT05629767</nct_id>
  </id_info>
  <brief_title>Tracking of Lipid Lowering Therapy in Jordan</brief_title>
  <acronym>JoLLA</acronym>
  <official_title>Tracking Lipid-Lowering Therapy Over One Year in Middle Eastern Patients With ASCVD. The Jordan LLA Tracking Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jordan Collaborating Cardiology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jordan Collaborating Cardiology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to examine the clinical practice of modifying the dose of&#xD;
      lipid-lowering therapy in patients with atherosclerotic cardiovascular disease (ASCVD), who&#xD;
      have LDL-C &gt; 70 mg/dl despite statin treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ASCVD is the leading cause of morbidity and mortality worldwide, in the Middle East and in&#xD;
      Jordan. One of the major risk factors that contribute to the development and progression of&#xD;
      ASCAD is dyslipidemia. A large number of clinical trials have reported the benefits of&#xD;
      lowering LDL-C, in reducing the mortality rate among ASCAD patients.&#xD;
&#xD;
      The 2019 ACC/AHA blood cholesterol treatment guideline to reduce atherosclerotic&#xD;
      cardiovascular risk in adults has expanded the role of LDL-C targets and reiterated the&#xD;
      importance of achieving an LDL-C level of 70 mg/dl or less for patients who have ASCVD.&#xD;
&#xD;
      Patients on statins and other lipid-lowering therapy in Jordan have not been tracked in the&#xD;
      past for the potential of up escalating the lipid-lowering therapy to reach the LDL-C target.&#xD;
&#xD;
      The investigation will enroll patients with ASCVD who have LAL-C &gt;70 mg/dl on lipid-lowering&#xD;
      therapy and follow them for 12 months to examine the treating physicians' action in&#xD;
      up-titrating the lipid-lowering therapy dose(s) and the frequency of measuring serum lipids&#xD;
      during the study period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2022</start_date>
  <completion_date type="Anticipated">July 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 13, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Achieving a target LDL-C bloob level of 70 mg/dl or less</measure>
    <time_frame>12 months</time_frame>
    <description>At 1 year of follow up, all participants will have their blood lipid profile measured to examine the frequency of attaining an LDL-C level of 70 mg/dl or less</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modifying the dose and class of lipid-lowering therapy</measure>
    <time_frame>12 months</time_frame>
    <description>Up titrating the dose of the same lipid-lowering agent or adding new agent during the study period of 12 months. Agents available include statins, ezetimibe and PCSK9 inhibitors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical cardiovascular events</measure>
    <time_frame>12 months</time_frame>
    <description>The study will study the frequency of incident acute cardiovascular the participating individuals experienced. Such events include cardiovascular death, acute coronary syndrome, stroke, lower extremity acute arterial insufficiency, and arterial revascularization procedure (coronary and other arterial beds).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Patients with ASCVD</arm_group_label>
    <description>Patients with ASCVD on statins and LDL-C more than 70 mg/dl</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Investigators will enroll adults aged 18 years or old with a diagnosis of atherosclerotic&#xD;
        cardiovascular disease on lipid-lowering therapy (statins and non-statins) and an LDL-C &gt;&#xD;
        70mg/dl. and follow them up for 12 months to evaluate the up-titrating of the&#xD;
        lipid-lowering therapy and the frequency of repeating the lipid measurement.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Adults aged 18 years or old.&#xD;
&#xD;
          2. Presence of atherosclerotic cardiovascular disease on lipid-lowering therapy.&#xD;
&#xD;
          3. LDL-C &gt; 70mg/dl.&#xD;
&#xD;
          4. Willingness to sign an informed consent.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Life-threatening disease with limited survival.&#xD;
&#xD;
          2. Unwillingness to sign an informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayman Hammoudeh, MD FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istishari Hospital, Amman, Jordan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayman Hammoudeh, MD FACC</last_name>
    <phone>0096265001000</phone>
    <email>a.hammoudeh@istisharihospital.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wesam Al Saud, PharmD</last_name>
    <phone>00965001000</phone>
    <email>researchculture2020@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istishari Hospital</name>
      <address>
        <city>Amman</city>
        <zip>11184</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayman Hammoudeh, MD, FACC</last_name>
      <phone>0096265001000</phone>
      <email>a.hammoudeh@istisharihospital.com</email>
    </contact>
    <contact_backup>
      <last_name>Wesam Alsaud, PharmD</last_name>
      <phone>00962780817273</phone>
      <email>wessam.alsaud@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Abdali Hospital</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ramzi Tabbalat, MD FACC</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <results_reference>
    <citation>Shi A, Tao Z, Wei P, Zhao J. Epidemiological aspects of heart diseases. Exp Ther Med. 2016 Sep;12(3):1645-1650. doi: 10.3892/etm.2016.3541. Epub 2016 Jul 26.</citation>
    <PMID>27602082</PMID>
  </results_reference>
  <results_reference>
    <citation>Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934. doi: 10.1016/j.jacc.2013.11.002. Epub 2013 Nov 12. No abstract available. Erratum In: J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):3024-3025. J Am Coll Cardiol. 2015 Dec 22;66(24):2812.</citation>
    <PMID>24239923</PMID>
  </results_reference>
  <results_reference>
    <citation>Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019 Jun 25;73(24):3210-3227. doi: 10.1016/j.jacc.2018.11.004. Epub 2018 Nov 10. Erratum In: J Am Coll Cardiol. 2019 Jun 25;73(24):3242.</citation>
    <PMID>30423394</PMID>
  </results_reference>
  <results_reference>
    <citation>Bloom BS. Effects of continuing medical education on improving physician clinical care and patient health: a review of systematic reviews. Int J Technol Assess Health Care. 2005 Summer;21(3):380-5. doi: 10.1017/s026646230505049x.</citation>
    <PMID>16110718</PMID>
  </results_reference>
  <results_reference>
    <citation>Santi RL, Martinez F, Baranchuk A, Liprandi AS, Piskorz D, Lorenzatti A, Santi MPL, Kaski JC. Management of Dyslipidaemia in Real-world Clinical Practice: Rationale and Design of the VIPFARMA ISCP Project. Eur Cardiol. 2021 Apr 27;16:e16. doi: 10.15420/ecr.2020.42. eCollection 2021 Feb.</citation>
    <PMID>33995586</PMID>
  </results_reference>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>October 29, 2022</study_first_submitted>
  <study_first_submitted_qc>November 23, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>February 16, 2023</last_update_submitted>
  <last_update_submitted_qc>February 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low-density lipoprotein cholesterol (LDL-C), Target levels</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 6, 2022</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT05629767/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

